AVTR vs. RGEN: Avantor vs. Repligen Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Repligen (RGEN) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Avantor (AVTR) and Repligen (RGEN)
Profile Item	AVTR	RGEN
Name	Avantor, Inc.	Repligen Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	10.48 billion USD	11.09 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	April 29, 1986
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

RGEN

GSPC

Avantor (AVTR) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Repligen (RGEN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Repligen (RGEN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Total Return (1Y)	36.41%	23.28%
Total Return (3Y, Annualized)	-5.02%	6.20%
Total Return (5Y, Annualized)	-16.62%	-8.41%

Risk Profile

Drawdown History

AVTR

RGEN

GSPC

Avantor (AVTR) vs. Repligen (RGEN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Repligen (RGEN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Volatility (1Y, Annualized)	43.39%	46.73%
Beta (5Y)	0.94	1.11
Max Drawdown (5Y)	-82.42%	-64.67%
Avg. Volume (3M)	8.56M	1.18M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and RGEN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Sharpe Ratio (1Y)	0.74	0.41
Sortino Ratio (1Y)	1.17	0.60

Profitability

ROE (TTM)

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Avantor (AVTR) reports 5.91%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max: 109.18%
Q3: 6.23%
RGEN: -0.57%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Avantor (AVTR) reports 5.08%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
RGEN: -1.47%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Avantor (AVTR) at 8.19% and Repligen (RGEN) at 6.19% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max: 83.12%
Q3: 14.77%
RGEN: 6.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
ROE (TTM)	5.91%	-0.57%
ROA (TTM)	2.83%	1.40%
Net Margin (TTM)	5.08%	-1.47%
Operating Margin (TTM)	8.19%	6.19%
Gross Margin (TTM)	31.59%	53.77%

Growth

Revenue Growth

Repligen (RGEN) at 16.36% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Revenue Growth (YoY)	-3.41%	16.36%
Revenue Growth (3Y CAGR)	-4.46%	-2.70%
EPS Growth (YoY)	-175.00%	--
EPS Growth (3Y CAGR)	--	-35.73%

Financial Strength

Current Ratio (MRQ)

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max: 25.13
Q3: 12.13
RGEN: 9.88
Median: 5.52
Q1: 2.47
Min: 0.10

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Avantor (AVTR) at 0.63 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max: 1.42
Q3: 0.65
RGEN: 0.33
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Current Ratio (MRQ)	1.89	9.88
Debt / Equity (MRQ)	0.63	0.33
Net Debt / EBITDA	3.40	-1.19

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RGEN: --

Avantor (AVTR) vs. Repligen (RGEN): RGEN does not report P/E ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max: 58.18
Q3: 25.77
RGEN: 13.77
Median: 7.30
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Avantor (AVTR) at 1.80 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
RGEN: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Repligen (RGEN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Repligen (RGEN)
Metric	AVTR	RGEN
P/E Ratio (TTM)	30.94	--
P/S Ratio (TTM)	1.58	13.77
P/B Ratio (MRQ)	1.80	4.70
Free Cash Flow Yield (TTM)	4.21%	1.01%